ArticleBMC urology2025
Smaller scopes, bigger impact: retrospective outcomes of minimally invasive holmium enucleation of the prostate (MILEP).
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHolmium laser enucleation of the prostate (HoLEP) is a size-independent and durable treatment, traditionally performed using 26-28 Fr resectoscopes. While larger scopes offer improved visualization and irrigation, they may increase the risk of urethral trauma and strictures. A 22 Fr HoLEP system has recently been introduced, aiming to minimize morbidity without compromising surgical efficiency. This study evaluates perioperative outcomes, safety, and early functional results using the 22 Fr HoLEP system for Minimally Invasive Laser Enucleation of the Prostate (MiLEP).
methodsWe conducted a retrospective review of a database of patients who underwent MiLEP between January 2022 and September 2024. Inclusion criteria were age ≥ 40, prostate volume ≥ 35 cm³, and moderate-to-severe lower urinary tract symptoms (LUTS). Preoperative, intraoperative, and postoperative data were analyzed, including IPSS, PSA, uroflowmetry (Qmax), post-void residual (PVR), complications, and need for urethral or meatal dilation. All procedures utilized the 22 Fr resectoscope with a 100 W holmium laser using an en bloc technique.
resultsAll cases were successfully completed using the MiLEP system without scope upsizing or conversion. Mean prostate volume was 84.5 ± 36.3 cm³, operative time was 76.1 ± 21.6 min, and morcellation time was 20.7 ± 6.8 min. Meatal dilation was required in 4% of cases; no patients required urethral dilation. Capsular perforation occurred in 7%, and 1% experienced non-perforating bladder injury during morcellation. No blood transfusions or intraoperative conversions were required. At 3 months, IPSS improved from 24.4 ± 3.7 to 6.7 ± 1.4 (p < 0.001), Qmax increased from 9.0 ± 2.8 to 21.1 ± 6.3 mL/s (p < 0.001), and PSA decreased from 5.7 ± 3.7 to 0.48 ± 0.3 ng/mL (p < 0.001). De novo stress urinary incontinence was reported in 3% of patients. No urethral strictures or bladder neck contractures were observed.
conclusionsMiLEP using the 22 Fr system is a feasible and effective technique for BPH treatment, offering significant improvements in LUTS and urinary flow with minimal morbidity. This approach may reduce the risk of urethral trauma and postoperative complications while maintaining surgical efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.